Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors

被引:0
作者
Prud'homme, GJ
机构
[1] McGill Univ, Dept Pathol, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada
关键词
autoimmunity; cytokine; interferon; gene therapy; interleukin-1 receptor antagonist; naked DNA; T lymphocytes; transforming growth factor beta; tumor necrosis factor;
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Gene therapy offers advantages for the immunotherapeutic delivery of cytokines or their inhibitors. After gene transfer, these mediators are produced at relatively constant, non-toxic levels and sometimes in a tissue-specific manner, obviating limitations of protein administration. Therapy with viral or nonviral vectors is effective in several animal models of autoimmunity including Type 1 diabetes mellitus (DM), experimental allergic encephalomyelitis (EAE), systemic lupus erythematosus ISLE), colitis, thyroiditis and various forms of arthritis. Genes encoding transforming growth factor beta, interleukin-4 (IL-4) and IL-10 are most frequently protective. Autoimmune/ inflammatory diseases are associated with excessive production of inflammatory cytokines such as IL-1, IL-12, tumor necrosis factor alpha (TNF alpha) and interferon gamma (IFN gamma). Vectors encoding inhibitors of these cytokines, such as IL-1 receptor antagonist, soluble IL-1 receptors, IL-12p40, soluble TNF alpha receptors or IFN; -receptor/IgG-Fc fusion proteins are protective in models of either arthritis, Type 1 DM, SLE or EAE. We use intramuscular injection of naked plasmid DNA for cytokine or anticytokine therapy. Muscle tissue is accessible, expression is usually more persistent than elsewhere, transfection efficiency can be increased by low-voltage in vivo electroporation, vector administration is simple and the method is inexpensive. Plasmids do not induce neutralizing immunity allowing repeated administration, and are suitable for the treatment of chronic immunological diseases. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:222 / 232
页数:11
相关论文
共 50 条
[41]   Gene Therapy for Hepatocellular Carcinoma Using Adenoviral Vectors Delivering a Gene Encoding IL-17A-Neutralizing Antibody Fragments [J].
Zou, Haoyu ;
Tuhin, Israth Jahan ;
Monty, Masuma Akter ;
Luo, Shenggen ;
Shao, Jiaqi ;
Yan, Zhiqiang ;
Yu, Lei .
HUMAN GENE THERAPY, 2020, 31 (19-20) :1074-1085
[42]   Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases [J].
Berns, Kenneth I. ;
Srivastava, Arun .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2019, 48 (02) :319-+
[43]   B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies [J].
Puri, Kamal D. ;
Di Paolo, Julie A. ;
Gold, Michael R. .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2013, 32 (04) :397-427
[44]   Aggressive Periodontitis and Chronic Arthritis: Blood Mononuclear Cell Gene Expression and Plasma Protein Levels of Cytokines and Cytokine Inhibitors [J].
Sorensen, Lars K. ;
Havemose-Poulsen, Anne ;
Bendtzen, Klaus ;
Holmstrup, Palle .
JOURNAL OF PERIODONTOLOGY, 2009, 80 (02) :282-289
[45]   Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach [J].
Martino, G ;
Poliani, PL ;
Furlan, R ;
Marconi, P ;
Glorioso, JC ;
Adorini, L ;
Comi, G .
JOURNAL OF NEUROIMMUNOLOGY, 2000, 107 (02) :184-190
[46]   The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system [J].
Furlan, R ;
Pluchino, S ;
Martino, G .
CURRENT OPINION IN NEUROLOGY, 2003, 16 (03) :385-392
[47]   Syngeneic fibroblasts transfected with a plasmid encoding interleukin-4 as non-viral vectors for anti-inflammatory gene therapy in collagen-induced arthritis [J].
Bessis, N ;
Cottard, V ;
Saidenberg-Kermanach, N ;
Lemeiter, D ;
Fournier, C ;
Boissier, MC .
JOURNAL OF GENE MEDICINE, 2002, 4 (03) :300-307
[48]   Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein [J].
G J Prud’homme ;
Y Chang .
Gene Therapy, 1999, 6 :771-777
[49]   Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein [J].
Prud'homme, GJ ;
Chang, Y .
GENE THERAPY, 1999, 6 (05) :771-777